Patent Grant
10610292
The present disclosure relates to neuromodulation and, more particularly, to devices, systems, and methods for monitoring and/or controlling deployment of a neuromodulation element within a body lumen and related technology.
The sympathetic nervous system (SNS) is a primarily involuntary bodily control system typically associated with stress responses. SNS fibers that innervate tissue are present in almost every organ system of the human body and can affect characteristics such as pupil diameter, gut motility, and urinary output. Such regulation can have adaptive utility in maintaining homeostasis or preparing the body for rapid response to environmental factors. Chronic activation of the SNS, however, is a common maladaptive response that can drive the progression of many disease states. Excessive activation of the renal SNS in particular has been identified experimentally and in humans as a likely contributor to the complex pathophysiology of hypertension, states of volume overload (such as heart failure), and progressive renal disease. For example, radiotracer dilution has demonstrated increased renal norepinephrine (“NE”) spillover rates in patients with essential hypertension.
Cardio-renal sympathetic nerve hyperactivity can be particularly pronounced in patients with heart failure. For example, an exaggerated NE overflow from the heart and kidneys is often found in these patients. Heightened SNS activation commonly characterizes both chronic and end stage renal disease. In patients with end stage renal disease, NE plasma levels above the median have been demonstrated to be predictive of cardiovascular diseases and several causes of death. This is also true for patients suffering from diabetic or contrast nephropathy. Evidence suggests that sensory afferent signals originating from diseased kidneys are major contributors to initiating and sustaining elevated central sympathetic outflow.
Sympathetic nerves innervating the kidneys terminate in the blood vessels, the juxtaglomerular apparatus, and the renal tubules. Stimulation of the renal sympathetic nerves can cause increased renin release, increased sodium (Na+) reabsorption, and a reduction of renal blood flow. These neural regulation components of renal function are considerably stimulated in disease states characterized by heightened sympathetic tone and likely contribute to increased blood pressure in hypertensive patients. The reduction of renal blood flow and glomerular filtration rate that result from renal sympathetic efferent stimulation are likely a cornerstone of the loss of renal function in cardio-renal syndrome (i.e., renal dysfunction as a progressive complication of chronic heart failure). Pharmacologic strategies to thwart the consequences of renal efferent sympathetic stimulation include centrally acting sympatholytic drugs, beta blockers (intended to reduce renin release), angiotensin converting enzyme inhibitors and receptor blockers (intended to block the action of angiotensin II and aldosterone activation consequent to renin release), and diuretics (intended to counter the renal sympathetic mediated sodium and water retention). These pharmacologic strategies, however, have significant limitations including limited efficacy, compliance issues, side effects, and others.
Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present disclosure.
The present technology is generally directed to devices, systems, and methods for monitoring and/or controlling deployment of a neuromodulation element within a body lumen and related technology. Among other contexts, the present technology can be useful in the context of electrically- and/or thermally-induced renal neuromodulation, which is described in detail below. In at least some embodiments, one or more pre-neuromodulation parameters are measured and analyzed to evaluate electrode contact, to customize power delivery via an electrode, and/or for another suitable purpose. Impedance through an electrical circuit at a treatment site is one example of a potentially useful parameter. Impedance or another suitable monitored parameter can be analyzed based on defined criteria. Based on this analysis, one or more aspects of a neuromodulation treatment may be controlled, customized, or otherwise modified to enhance the treatment.
Methods in accordance with at least some embodiments of the present technology allow for enhanced verification of adequate deployment of a neuromodulation element at a treatment site (e.g., adequate contact between an electrode of a neuromodulation element and tissue at a treatment site) prior to initiating energy delivery. This can be a significant advantage over conventional counterparts. For example, with at least some conventional neuromodulation systems, inadequate deployment of a neuromodulation element can only be detected after energy delivery has been initiated, such as by recognizing a less than expected increase in temperature at a treatment site. This approach is suboptimal at least because it can be difficult to account for partial treatment, if any, that occurred before inadequate deployment of a neuromodulation element is recognized.
Methods in accordance with at least some embodiments of the present technology include using impedance for the purpose of detecting inadequate deployment of a neuromodulation element. In a particular embodiment, a method includes advancing a catheter including an elongate shaft and a neuromodulation element operably connected to the shaft toward a treatment location within a body lumen of a human patient. The neuromodulation element can include an elongate electrode slidably disposed within a dielectric sleeve. After advancing the catheter, the neuromodulation element can be deployed at the treatment location. In one embodiment, deployment of the neuromodulation element can include a first deployment phase during which an electrode of the neuromodulation element moves radially outward while a first interface area between the electrode and the dielectric sleeve decreases and a second interface area between the electrode and a biological fluid (e.g. blood) at the treatment location increases. The first deployment phase can be followed by a second deployment phase during which the first interface decreases and a third interface area between the electrode and a lumen wall at the treatment location increases. The second deployment phase can be followed by a third deployment phase during which the electrode moves radially outward and the third interface area is more stable than it is during the second deployment phase. While deploying the neuromodulation element, the electrode can measure an electrical property of a sum of material adjacent to the electrode. The sum of material adjacent to the electrode can include portions of the dielectric sleeve, the lumen wall and the biological fluid adjacent to the electrode. The method can further include detecting a transition of the electrical property corresponding to a transition from the first deployment phase to the second deployment phase and generating a status indication, enabling a neuromodulation treatment, or both in response to detecting the transition of the electrical property.
As an additional or alternative advantage, methods in accordance with at least some embodiments of the present technology allow a transverse cross-sectional dimension (e.g., diameter) at a treatment site to be determined prior to initiating energy delivery. This can be useful to allow subsequent energy delivery to be customized according to the determined dimension. For example, a treatment carried out in a small blood vessel may call for less energy to be delivered relative to a treatment carried out in a larger blood vessel. In a particular embodiment, methods include advancing a catheter including an elongate shaft and a neuromodulation element operably connected to the shaft toward a treatment location within a body lumen of a human patient. The neuromodulation element can include an elongate electrode slidably disposed within a dielectric sleeve. The elongate control member can be moved relative to the shaft and/or the shaft can be moved relative to the control member so as to cause a longitudinal shift between the control member and the shaft. The longitudinal shift can cause the electrode to move radially outward while a wall-interface area between the electrode and a lumen wall at the treatment location increases. While moving the control member, the longitudinal shift can be measured. While the electrode moves radially outward, an electrical property of a sum of material adjacent to the electrode can be measured. The sum of material adjacent to the electrode can include portions of the dielectric sleeve, the lumen wall and the biological fluid adjacent to the electrode. The method can further include detecting a transition of the electrical property corresponding to a stabilization of the wall-interface area. E.g., physical stability of the electrode with respect to the lumen wall causes the size of the wall-interface area to become constant or nearly so, as detected by the measured electrical property. Energy may be delivered to one or more nerves of the patient via the electrode according to a profile of energy over time. The profile of energy can be based on the longitudinal shift at the time of the transition of the electrical property, and the longitudinal shift at the time of the transition of the electrical property can correspond to a diameter of the body lumen.
Specific details of several embodiments of the present technology are described herein with reference to
As used herein, the terms “distal” and “proximal” define a position or direction with respect to the treating clinician or clinician's control device (e.g., a handle assembly). “Distal” or “distally” can refer to a position distant from or in a direction away from the clinician or clinician's control device. “Proximal” and “proximally” can refer to a position near or in a direction toward the clinician or clinician's control device. The term “area” as used herein with respect to an electrode refers to a surface area and can refer to a size of a particular surface area, e.g. “fluid-interface area” of an electrode.
The proximal end of the therapeutic assembly 21 is carried by or affixed to the distal portion 20 of the elongate shaft 16. A distal end of the therapeutic assembly 21 may terminate with, for example, an atraumatic rounded tip or cap (e.g., cover 129 in
The energy source or console 26 can be configured to generate a selected form and/or magnitude of energy for delivery to a target treatment site via the electrodes 202, 204. For example, the console 26 can include an energy generator configured to generate radio frequency (RF) energy, pulsed energy, microwave energy, optical energy, ultrasound energy (e.g., intravascularly delivered ultrasound, extracorporeal ultrasound, high-intensity focused ultrasound (HIFU)), direct heat energy, radiation (e.g., infrared, visible, gamma), or another suitable type of energy. In a particular embodiment, the console 26 includes an RF generator operably coupled to the electrodes 202, 204. The console 26 can be configured to control, monitor, supply, or otherwise support operation of the catheter 12. A control mechanism, such as a foot pedal 32, may be connected (e.g., pneumatically connected or electrically connected) to the console 26 to allow an operator to initiate, terminate and/or adjust various operational characteristics of the energy generator, such as power delivery.
The energy console 26 can be electrically coupled to the neuromodulation (treatment) device 12 via a cable 28. At least one supply wire (not shown) passes along the elongated shaft 16 or through a lumen in the elongated shaft 16 to the one or more wire electrodes 202, 204 and transmits the treatment energy to the one or more wire electrodes 202, 204. In some embodiments, each helical push wire electrode 202, 204 includes its own supply wire which would allow for each helical push wire electrode 202, 204 to be independently energized in a sequential or exclusive manner. In other embodiments, however, the wire electrodes 202, 204 may be electrically coupled to the same supply wire. The supply wire may be used as a thermocouple wire and may be used to transmit temperature and impedance measurements taken at the distal cap.
The console 26 can be configured to deliver neuromodulation energy according to one or more automated control algorithms 30 and/or manually under the control of a clinician. The control algorithms 30 can be executed using a processor (not shown) of the system 10 to control the delivery of power to the neuromodulation element 21. In some embodiments, selection of a control algorithm 30 for a particular patient may be guided by one or more diagnostic algorithms 33 that include measuring and evaluating one or more parameters prior to energy delivery. For example, the diagnostic algorithms 33 can provide patient-specific feedback to a clinician who can use the feedback to select an appropriate control algorithm 30 and/or to modify a previously selected control algorithm 30. Further details regarding control algorithms 30 are described below with reference to
The electrodes 202, 204 may be configured to deliver power independently (e.g., in a monopolar fashion) simultaneously, selectively, and/or sequentially. Alternatively or in addition, the electrodes 202, 204 may be configured to deliver power collectively (e.g., in a bipolar fashion). In monopolar embodiments, a neutral or dispersive electrode 38 may be electrically connected to the console 26 and attached to the exterior of a patient. Furthermore, a clinician may optionally choose which electrodes 202, 204 are used for power delivery in order to form highly customized lesion(s) having a variety of shapes or patterns.
The system 10 can further include a controller 42 having, for example, memory (not shown), storage devices (e.g., disk drives), one or more output devices (e.g., a display), one or more input devices (e.g., a keyboard, a touchscreen, etc.) and processing circuitry (not shown). The output devices may be configured to transmit signals to the catheter 12 (e.g., via the connector 28) to control power to the electrodes 202, 204. In some embodiments the output devices can be configured to obtain signals from the electrodes 202, 204 and/or any sensors associated with the catheter 12, such as a pressure sensor, temperature sensor, impedance sensor, flow sensor, chemical sensor, ultrasound sensor, optical sensor, or another suitable sensing device. The sensors (not shown) may be located proximate to or within the helical push wire electrodes 22 and connected to one or more supply wires (not shown). For example, a total of two supply wires may be included, in which both wires could transmit the signal from the sensor and one wire could serve dual purpose and also convey the energy to the helical push wire electrodes 22. Alternatively, a different number of supply wires may be used to transmit energy to the helical push wire electrodes 22.
The indicator 40 of the system 10 can serve as an output device and may be a standalone device or may alternatively be associated with the console 26 and/or the handle 34. The indicator 40 can include one or more LEDs, a device configured to produce an audible indication, a display screen, and/or other suitable communicative devices. In some embodiments, the indicator 40 is interactive. For example, the indicator 40 can include a user interface that can receive user input and/or provide information to a user. As another example, the indicator 40 can include processing circuitry for monitoring the one or more sensors. Display devices may be configured to provide indications of power levels or sensor data, such as audio, visual or other indications, or may be configured to communicate the information to another device.
In some embodiments, the controller 42 is part of the console 26, as shown in
As shown in
At some point during deployment, the electrodes 202, 204 can begin to contact an inner surface S of the wall W of the renal artery RA. As this occurs, portions of each of the segments 201 previously in contact with biological fluid may instead begin to contact the wall W. Accordingly, a wall-interface area (i.e., the portion of each of the electrodes 202, 204 in contact with the wall W) may increase as the electrodes 202, 204 continue to expand and additional portions of the electrodes 202, 204 engage the wall W. Depending on the rate at which the segments 201 are lengthening and the rate at which the wall-interface area increases, the fluid-interface area and/or the sleeve-interface area of each of the electrodes 202, 204 can increase, decrease, and/or remain the same as the wall-interface area of each of the electrodes 202, 204 increases. For example, since the electrodes may still be expanding when first making contact with the wall W, if the rate at which the electrodes are expanding (and thus exposing additional portions of the electrodes) is greater than the rate at which the wall-interface area increases (rate at which additional portions of the electrodes contact the wall W), then the fluid-interface area may still be increasing.
Expansion of the electrodes 202, 204 can end once the electrodes 202, 204 are in stable apposition with an inner surface S of a wall W of the renal artery RA, as shown in
Before treatment begins, one or more of the diagnostic algorithms 33 can be used to monitor one or more operating parameters. Such operating parameters detected by the diagnostic algorithm(s) 33 include electrical properties (e.g., impedance, voltage, current, power, etc.), temperature, and/or blood flow parameters as compared to accepted or expected thresholds and/or predetermined or calculated ranges. For example, predetermined operating parameter thresholds and/or ranges can be empirically determined to create a look-up table. The look-up table may provide operating parameter thresholds and/or ranges for corresponding operating threshold values. Look-up table values can be empirically determined, for example, based on clinical studies.
Impedance is one example of an operating parameter that can be advantageous to monitor for several diagnostic reasons, one of which is to inform the clinician as to the existence and/or degree of contact between one or more of the electrode(s) and the lumen wall at the treatment location. For example,
During a second deployment phase (labeled as “Phase II” in
It will be appreciated that more or less than three deployment phases are within the scope of the present technology, and the terms “first,” “second,” and “third” are used only for ease of reference. Moreover, although the graphs shown in
Referring to
The shaft 125 and the distal electrode support section 122 may together define a lumen where the thermocouple wires 124 are disposed. The thermocouple wires 124 are disposed along or in parallel to the longitudinal axis B-B. In one embodiment, the thermocouple wires 124 may be fixed to the proximal end 122a of the distal electrode support section 122. In another embodiment, the thermocouple wires 124 may be fixed to the distal end 122b of the distal electrode support section 122.
In further embodiments, the helical push wire electrodes 123 may be coupled to the thermocouple wires 124 at the distal end 122b of the distal electrode support section 122. The helical push wire electrodes 123 and the thermocouple wires 124 may be coupled by soldering or by a mechanical lock. In one embodiment, the therapeutic assembly may comprise a cover 129 encasing the joint of the helical push wire electrodes and the thermocouple wires. The cover 129 may be made of various materials. In one embodiment, the cover 129 may be coated with Titanium Nitride (TiN). In further embodiments, the therapeutic assembly may comprise a temperature sensor, such as a thermometer. In one embodiment, the cover 129 encloses the temperature sensor. The cover 129 could also be used to electrically connect the supply wire to multiple wire electrodes (such as electrode 123). Accordingly, the same supply wire would also transmit temperature and impedance measurements. In embodiments having only a single electrode (not shown), the same supply wire may act as a TC wire which can transmit temperature and impedance.
Further, as illustrated in
The TC/supply wire pair 552a-b may run from the proximal end of the treatment device 12 (shown in
The distal tip 556 of the push wire electrode 550 could be covered with adhesive 555 which protects the distal tip, configures the distal tip to be atraumatic, as well as secures the TC/supply wires 552a-b into place. As with previous embodiments, the TC/supply wire pair 552a-b could act as a wire to provide temperature and impedance measurements as well as supply RF energy. Alternatively, RF energy could be supplied to the distal tip with a separate RF supply wire and within the lumen of the catheter, provided the RF supply wire is electrically coupled to the push wire electrode 550.
In an alternative embodiment (not shown), a single TC/supply wire could be provided for a plurality of push wire electrodes. In this embodiment, the push wire electrodes would be electrically coupled within the distal tip thus energizing all push wire electrodes simultaneously. The distal point of attachment of the TC/supply wire to the push wire electrode would be the measurement point of temperature. For certain embodiments, a single temperature measurement on a single push wire electrode could be sufficient.
Accordingly, the TC wires 552a-b would be measuring the temperature of the push wire electrode 550 at a much closer proximity to tissue. In embodiments where the TC wire terminates at the distal tip of the treatment device, the temperature would read near the center of the artery lumen. Reading temperature farther from the target tissue site as well as exposing the tip to a greater amount of blood flow could provide a less accurate tissue temperature, giving more of an estimate of tissue temperature.
When the neuromodulation element 621 is delivered to the renal artery in the delivery state, the radially interior portions of the treatment portions 609 are pressed up against or in full contact with the support member 624. As a result, only portions of the treatment portions 609 are exposed to the interior of the renal artery RA and thus define the fluid-interface area of the electrodes 602, 604. Once the neuromodulation element 621 is adequately positioned at the treatment site, the proximal ends of the electrodes 602, 604 can be pushed distally to begin transformation of the neuromodulation element 621 from its delivery state to its treatment state. As the electrodes 602, 604 radially expand, the treatment portions 609 move away from the support member 624, thereby exposing the previously unexposed portions of the treatment portions 609. During this time, the segments 601 lengthen as the exposed distal portions 603′, 605′ of the insulated portions 603, 605 increase in length. The treatment portions 609, however, remain generally the same length. As such, at least before the electrodes 602, 604 contact the wall of the renal artery, while the electrodes 602, 604 expand, the fluid-interface area of each of the electrodes 602, 604 can remain generally the same.
At some point during deployment, the first and second electrodes 602, 604 can begin to contact an inner surface of the wall of the renal artery. As this occurs, portions of each of the treatment portions 609 previously in contact with biological fluid may instead begin to contact the wall. Accordingly, a wall-interface area (i.e., the portion of each of the treatment portions 609 in contact with the wall) may increase as the electrodes 602, 604 continue to expand and additional portions of the treatment portions 609 engage the wall. For example, wall-interface areas 123c are illustrated in
A second phase of deployment (labeled as “Phase II” in
During a third deployment phase (labeled as “Phase III” in
It will be appreciated that more or less than four deployment phases are within the scope of the present technology, and the terms “first,” “second,” “third,” and “fourth” are used only for ease of reference. Moreover, although the graphs shown in
Based on the above-described relationships between deployment and impedance, one or more diagnostic algorithms can be used to detect stable contact between one or more of the electrodes and the lumen wall prior to initiating treatment and/or to provide feedback to a clinician as to the status of the contact. For example,
Before treatment begins, one or more diagnostic algorithms 33 can detect certain patient attribute(s) which denote a possibility that one or more of the control algorithm(s) 30 will not provide efficacious treatment to the particular patient and/or adequately evaluate patient-specific physiological parameters in response to neuromodulation. Such patient attributes detected by the diagnostic algorithm(s) 33 can include, for example, the inner diameter of the body lumen at the treatment location, that are outside of accepted or expected thresholds and/or predetermined or calculated ranges. Accordingly, evaluation of certain patient attributes by the diagnostic algorithm(s) 33 prior to beginning treatment can inform the clinician as to which control algorithm(s) 30 are most likely to provide successful neuromodulation to the individual patient. The diagnostic algorithm(s) 33 can indicate a particular control algorithm 30 via the indicator 40 based on the patient profile developed by the diagnostic algorithm 33 and/or the diagnostic algorithm 33 can cause the patient profile to be displayed or indicated to the clinician so that the clinician can make an informed selection of the appropriate control algorithm 30 and/or modification of the control algorithm 30. In some instances, the diagnostic algorithm 33 may indicate that the patient is not a good candidate for neuromodulation and the clinician may decide not to pursue treatment.
The inner diameter of the lumen at the treatment location can often be an important patient attribute since it can inform the clinician as to the appropriate control algorithm 30 or energy delivery profile to utilize during treatment. Lumen inner diameters can vary from patient to patient, and as a result, a standardized control algorithm(s) 30 may not be appropriate across all treatments. For example, if a patient has relatively large lumen inner diameter, the energy delivered may not reach a predetermined maximum power level before a predetermined treatment time expires (and before the tissue can be adequately heated by the electrodes). If a patient has relatively small lumen inner diameter, the electrode(s) can heat up too quickly. Accordingly, disclosed herein are one or more diagnostic algorithms 33 that determine contact prior to initiating treatment and provide feedback to the clinician as to selection and/or modification of the control algorithm 30.
With the treatments disclosed herein for delivering neuromodulation treatment to target tissue, it may be beneficial for energy to be delivered to the target neural structures in a controlled manner. The controlled delivery of energy will allow the zone of thermal treatment to extend into the renal fascia while reducing undesirable energy delivery or thermal effects to the lumen wall. A controlled delivery of energy may also result in a more consistent, predictable and efficient overall treatment. Accordingly, the console 26 desirably includes a controller 42 (
For example,
The control algorithm 30 also can include continuously and/or periodically monitoring certain operating parameters such as time, electrical properties (e.g., impedance, voltage, current, power, etc.) and/or other suitable parameters. The control algorithm 30 can also include calculating and/or monitoring derivatives of such operating parameters, such as impedance over a specified time, a maximum impedance, a maximum average impedance, a minimum impedance, an impedance at a predetermined or calculated time relative to a predetermined or calculated impedance, an average impedance over a specified time, and other suitable derivatives. As used herein, “operating parameters” includes operating parameter measurements, derivatives, manipulations, etc. Measurements may be taken at one or more predetermined times, ranges of times, calculated times, and/or times when or relative to when a measured event occurs.
Renal neuromodulation is the partial or complete incapacitation or other effective disruption of nerves innervating the kidneys (e.g., rendering neural fibers inert or inactive or otherwise completely or partially reduced in function). For example, renal neuromodulation can include inhibiting, reducing, and/or blocking neural communication along neural fibers (i.e., efferent and/or afferent nerve fibers) innervating the kidneys. Such incapacitation can be long-term (e.g., permanent or for periods of months, years, or decades) or short-term (e.g., for periods of minutes, hours, days, or weeks). Renal neuromodulation is expected to efficaciously treat several clinical conditions characterized by increased overall sympathetic activity, and, in particular, conditions associated with central sympathetic overstimulation such as hypertension, heart failure, acute myocardial infarction, metabolic syndrome, insulin resistance, diabetes, left ventricular hypertrophy, chronic and end stage renal disease, inappropriate fluid retention in heart failure, cardio-renal syndrome, osteoporosis, and sudden death, among others. The reduction of afferent neural signals typically contributes to the systemic reduction of sympathetic tone/drive, and renal neuromodulation is expected to be useful in treating several conditions associated with systemic sympathetic overactivity or hyperactivity. Renal neuromodulation can potentially benefit a variety of organs and bodily structures innervated by sympathetic nerves.
Thermal effects can include both thermal ablation and non-ablative thermal alteration or damage (e.g., via sustained heating and/or resistive heating) to partially or completely disrupt the ability of a nerve to transmit a signal. Desired thermal heating effects, for example, may include raising the temperature of target neural fibers above a desired threshold to achieve non-ablative thermal alteration, or above a higher temperature to achieve ablative thermal alteration. For example, the target temperature can be above body temperature (e.g., approximately 37° C.) but less than about 45° C. for non-ablative thermal alteration, or the target temperature can be about 45° C. or higher for ablative thermal alteration. More specifically, exposure to thermal energy in excess of a body temperature of about 37° C., but below a temperature of about 45° C., may induce thermal alteration via moderate heating of target neural fibers or of vascular structures that perfuse the target fibers. In cases where vascular structures are affected, the target neural fibers may be denied perfusion resulting in necrosis of the neural tissue. For example, this may induce non-ablative thermal alteration in the fibers or structures. Exposure to heat above a temperature of about 45° C., or above about 60° C., may induce thermal alteration via substantial heating of the fibers or structures. For example, such higher temperatures may thermally ablate the target neural fibers or the vascular structures that perfuse the target fibers. In some patients, it may be desirable to achieve temperatures that thermally ablate the target neural fibers or the vascular structures, but that are less than about 90° C., or less than about 85° C., or less than about 80° C., and/or less than about 75° C. Other embodiments can include heating tissue to a variety of other suitable temperatures. Regardless of the type of heat exposure utilized to induce the thermal neuromodulation, a therapeutic effect (e.g., a reduction in renal sympathetic nerve activity (RSNA)) is expected.
Various techniques can be used to partially or completely incapacitate neural pathways, such as those innervating the kidneys. The purposeful application of energy (e.g., RF energy, mechanical energy, acoustic energy, electrical energy, thermal energy, etc.) to tissue and/or the purposeful removal of energy (e.g., thermal energy) from tissue can induce one or more desired thermal heating and/or cooling effects on localized regions of the tissue. The tissue, for example, can be tissue of the renal artery and adjacent regions of the renal plexus, which lay intimately within or adjacent to the adventitia of the renal artery. For example, the purposeful application and/or removal of energy can be used to achieve therapeutically effective neuromodulation along all or a portion of the renal plexus.
The following examples are illustrative of several embodiments of the present technology:
1. A method, comprising:
advancing a catheter including an elongate shaft and a neuromodulation element operably connected to the shaft toward a treatment location within a body lumen of a human patient, the neuromodulation element including an elongate electrode slidably disposed within a dielectric sleeve;
deploying the neuromodulation element from a delivery state to a treatment state after advancing the catheter, deploying the neuromodulation element including—
using the electrode to measure an electrical property of a sum of material adjacent to the electrode while deploying the neuromodulation element, the sum of material adjacent to the electrode including portions of the dielectric sleeve, the lumen wall and the biological fluid adjacent to the electrode;
detecting a transition of the electrical property corresponding to a transition from the second deployment phase to the third deployment phase; and
generating a status indication, enabling a neuromodulation treatment, or both in response to detecting the transition of the electrical property.
2. The method of example 1 wherein the electrical property is impedance.
3. The method of example 1 or example 2 wherein detecting the transition of the electrical property includes detecting a transition of a rate of change of the electrical property.
4. The method of example 1 or example 2 wherein detecting the transition of the electrical property includes:
detecting a rate of change of the electrical property to be greater than a first threshold rate of change for a first time period; and
detecting the rate of change of the electrical property to be less than a second threshold rate of change for a second time period after the first time period.
5. The method of any of examples 1-4 wherein the electrode is a wire electrode.
6. The method of example 5 wherein the wire electrode is at least generally helical during the third deployment phase.
7. The method of any of examples 1-6 wherein deploying the neuromodulation element includes pushing a proximal end of the electrode in a distal direction.
8. A method, comprising:
advancing a catheter including an elongate shaft and a neuromodulation element operably connected to the shaft toward a treatment location within a body lumen of a human patient, the neuromodulation element including a first elongate electrode slidably disposed within a first dielectric sleeve and a second elongate electrode slidably disposed within a second dielectric sleeve;
deploying the first electrode after advancing the catheter, deploying the first electrode including—
deploying the second electrode after advancing the catheter, deploying the second electrode including—
using the first electrode to measure a first electrical property of a first sum of material adjacent to the first electrode while deploying the neuromodulation element, the first sum of material adjacent to the first electrode including portions of the first dielectric sleeve, the lumen wall and the biological fluid adjacent to the first electrode;
using the second electrode to measure a second electrical property of a second sum of material adjacent to the second electrode while deploying the neuromodulation element, the second sum of material adjacent to the second electrode including portions of the second dielectric sleeve, the lumen wall and the biological fluid adjacent to the second electrode;
detecting a transition of the first electrical property corresponding to a transition from the second deployment phase of deploying the first electrode to the third deployment phase of deploying the first electrode;
detecting a transition of the second electrical property corresponding to a transition from the second deployment phase of deploying the second electrode to the third deployment phase of deploying the second electrode; and
generating a status indication, enabling a neuromodulation treatment, or both in response to detecting the transition of the first electrical property, second electrical property, or both.
9. The method of example 8 wherein generating a status indication, enabling a neuromodulation treatment, or both is in response to detecting an intervening time period between the transition of the first electrical property and the transition of the second electrical property that is less than a threshold time period.
10. The method of example 8 or example 9 wherein:
the first electrical property is a first impedance; and
the second electrical property is a second impedance.
11. The method of any of examples 8-10 wherein:
detecting the transition of the first electrical property includes detecting a transition of a rate of change of the first electrical property; and
detecting the transition of the second electrical property includes detecting a transition of a rate of change of the second electrical property.
12. The method of any of examples 8-10 wherein:
detecting the transition of the first electrical property includes—
detecting the transition of the second electrical property includes—
13. The method of example 12 wherein:
the first and third threshold rates of change are the same;
the first and third time periods are the same;
the second and fourth threshold rates of change are the same; and
the second and fourth time periods are the same.
14. The method of any of examples 8-13 wherein:
the first electrode is a first wire electrode; and
the second electrode is a second wire electrode.
15. The method of example 14 wherein:
the first wire electrode is at least generally helical during the third deployment phase of deploying the first wire electrode; and
the second wire electrode is at least generally helical during the third deployment phase of deploying the second wire electrode.
16. The method of example 15 wherein the first and second wire electrodes are helically intertwined during the third deployment phase of deploying the first wire electrode and during the third deployment phase of deploying the second wire electrode.
17. A method, comprising:
advancing a catheter including an elongate shaft and a neuromodulation element operably connected to the shaft toward a treatment location within a body lumen of a human patient, the neuromodulation element including an elongate electrode slidably disposed within a dielectric sleeve;
moving an elongate control member relative to the shaft, moving the shaft relative to the control member, or both so as to cause a longitudinal shift between the control member and the shaft and thereby cause the electrode to move radially outward while a wall-interface area between the electrode and a lumen wall at the treatment location increases;
measuring the longitudinal shift while moving the control member;
using the electrode to measure an electrical property of a sum of material adjacent to the electrode while the electrode moves radially outward, the sum of material adjacent to the electrode including portions of the dielectric sleeve, the lumen wall and the biological fluid adjacent to the electrode,
detecting a transition of the electrical property corresponding to a stabilization of the wall-interface area; and
delivering energy to one or more nerves of the patient via the electrode according to a profile of energy over time, the profile being based on the longitudinal shift at the time of the transition of the electrical property, the longitudinal shift at the time of the transition of the electrical property corresponding to a diameter of the body lumen.
18. The method of example 17 wherein delivering energy to the one or more nerves via the electrode includes delivering a greater amount of energy to the one or more nerves when the longitudinal shift at the time of the transition of the electrical property is relatively large and delivering a lesser amount of energy to the one or more nerves when the longitudinal shift at the time of the transition of the electrical property is relatively small.
19. The method of example 17 wherein delivering energy to the one or more nerves via the electrode includes delivering energy to the one or more nerves for a longer time period when the longitudinal shift at the time of the transition of the electrical property is relatively large and energy to the one or more nerves for a shorter time period when the longitudinal shift at the time of the transition of the electrical property is relatively small.
20. The method of any of examples 17-19, further including indicating the diameter of the body lumen.
21. A method, comprising:
advancing a catheter including an elongate shaft and a neuromodulation element operably connected to the shaft toward a treatment location within a body lumen of a human patient, the neuromodulation element including an elongate electrode slidably disposed within a dielectric sleeve;
deploying the neuromodulation element from a delivery state to a treatment state after advancing the catheter, deploying the neuromodulation element including—
using the electrode to measure an electrical property of a sum of material adjacent to the electrode while deploying the neuromodulation element, the sum of material adjacent to the electrode including portions of the dielectric sleeve, the lumen wall and the biological fluid adjacent to the electrode;
detecting a transition of the electrical property corresponding to a transition from the third deployment phase to the fourth deployment phase; and
generating a status indication, enabling a neuromodulation treatment, or both in response to detecting the transition of the electrical property.
22. The method of example 21 wherein the electrical property is impedance.
23. The method of example 21 or example 22 wherein detecting the transition of the electrical property includes detecting a transition of a rate of change of the electrical property.
24. The method of example 21 or example 22 wherein detecting the transition of the electrical property includes:
detecting a rate of change of the electrical property to be greater than a first threshold rate of change for a first time period; and
detecting the rate of change of the electrical property to be less than a second threshold rate of change for a second time period after the first time period.
25. The method of any of examples 21-24 wherein the electrode is a wire electrode.
26. The method of example 25 wherein the wire electrode is at least generally helical during the fourth deployment phase.
27. The method of any of examples 21-26 wherein deploying the neuromodulation element includes pushing a proximal end of the electrode in a distal direction.
The above detailed descriptions of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology, as those skilled in the relevant art will recognize. For example, while steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms may also include the plural or singular term, respectively.
Certain aspects of the present technology may take the form of computer-executable instructions, including routines executed by a controller or other data processor. In some embodiments, a controller or other data processor is specifically programmed, configured, and/or constructed to perform one or more of these computer-executable instructions. Furthermore, some aspects of the present technology may take the form of data (e.g., non-transitory data) stored or distributed on computer-readable media, including magnetic or optically readable and/or removable computer discs as well as media distributed electronically over networks. Accordingly, data structures and transmissions of data particular to aspects of the present technology are encompassed within the scope of the present technology. The present technology also encompasses methods of both programming computer-readable media to perform particular steps and executing the steps.
Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with certain embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
This application claims the benefit of U.S. Provisional Patent Application No. 61/984,533, filed on Apr. 25, 2014 and U.S. Provisional Patent Application No. 61/984,170, filed on Apr. 25, 2014, the disclosures of both applications being incorporated by reference herein in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4602624 | Naples et al. | Jul 1986 | A |
| 4649936 | Ungar et al. | Mar 1987 | A |
| 4709698 | Johnston et al. | Dec 1987 | A |
| 4764504 | Johnson et al. | Aug 1988 | A |
| 4890623 | Cook et al. | Jan 1990 | A |
| 4976711 | Parins et al. | Dec 1990 | A |
| 5228442 | Imran | Jul 1993 | A |
| 5300068 | Rosar et al. | Apr 1994 | A |
| 5301683 | Durkan | Apr 1994 | A |
| 5358514 | Schulman et al. | Oct 1994 | A |
| 5368591 | Lennox et al. | Nov 1994 | A |
| 5423744 | Gencheff et al. | Jun 1995 | A |
| 5423808 | Edwards et al. | Jun 1995 | A |
| 5423810 | Goble et al. | Jun 1995 | A |
| 5425364 | Imran | Jun 1995 | A |
| 5437662 | Nardella | Aug 1995 | A |
| 5437664 | Cohen et al. | Aug 1995 | A |
| 5472443 | Cordis et al. | Dec 1995 | A |
| 5484400 | Edwards et al. | Jan 1996 | A |
| 5496312 | Klicek | Mar 1996 | A |
| 5540681 | Strul et al. | Jul 1996 | A |
| 5540684 | Hassler, Jr. | Jul 1996 | A |
| 5562721 | Marchlinski et al. | Oct 1996 | A |
| 5571147 | Sluijter et al. | Nov 1996 | A |
| 5573533 | Strul | Nov 1996 | A |
| 5584830 | Ladd et al. | Dec 1996 | A |
| 5588964 | Imran et al. | Dec 1996 | A |
| 5599345 | Edwards et al. | Feb 1997 | A |
| 5626576 | Janssen | May 1997 | A |
| 5658619 | Kirschner et al. | Aug 1997 | A |
| 5672174 | Gough et al. | Sep 1997 | A |
| 5688266 | Edwards et al. | Nov 1997 | A |
| 5697882 | Eggers et al. | Dec 1997 | A |
| 5697925 | Taylor | Dec 1997 | A |
| 5700282 | Zabara | Dec 1997 | A |
| 5702386 | Stern et al. | Dec 1997 | A |
| 5707400 | Terry, Jr. et al. | Jan 1998 | A |
| 5735846 | Panescu et al. | Apr 1998 | A |
| 5755715 | Stern et al. | May 1998 | A |
| 5769847 | Panescu et al. | Jun 1998 | A |
| 5772590 | Webster, Jr. | Jun 1998 | A |
| 5810802 | Panescu et al. | Sep 1998 | A |
| 5817092 | Behl | Oct 1998 | A |
| 5817093 | Williamson, IV et al. | Oct 1998 | A |
| 5860974 | Abele | Jan 1999 | A |
| 5865787 | Shapland et al. | Feb 1999 | A |
| 5868737 | Taylor et al. | Feb 1999 | A |
| 5871481 | Kannenberg et al. | Feb 1999 | A |
| 5893885 | Webster et al. | Apr 1999 | A |
| 5906614 | Stern et al. | May 1999 | A |
| 5907589 | Koifman et al. | May 1999 | A |
| 5944710 | Dev et al. | Aug 1999 | A |
| 5954719 | Chen et al. | Sep 1999 | A |
| 5976128 | Schilling et al. | Nov 1999 | A |
| 5983141 | Sluijter et al. | Nov 1999 | A |
| 6004269 | Crowley et al. | Dec 1999 | A |
| 6009877 | Edwards | Jan 2000 | A |
| 6023638 | Swanson | Feb 2000 | A |
| 6039731 | Taylor et al. | Mar 2000 | A |
| 6066134 | Eggers et al. | May 2000 | A |
| 6080149 | Huang et al. | Jun 2000 | A |
| 6099524 | Lipson et al. | Aug 2000 | A |
| 6113592 | Taylor | Sep 2000 | A |
| 6117101 | Diederich et al. | Sep 2000 | A |
| 6123702 | Swanson et al. | Sep 2000 | A |
| 6123703 | Tu et al. | Sep 2000 | A |
| 6135999 | Fanton et al. | Oct 2000 | A |
| 6142993 | Whayne et al. | Nov 2000 | A |
| 6149620 | Baker et al. | Nov 2000 | A |
| 6161048 | Sluijter et al. | Dec 2000 | A |
| 6183468 | Swanson et al. | Feb 2001 | B1 |
| 6197021 | Panescu et al. | Mar 2001 | B1 |
| 6210403 | Klicek | Apr 2001 | B1 |
| 6212426 | Swanson | Apr 2001 | B1 |
| 6217573 | Webster | Apr 2001 | B1 |
| 6219577 | Brown, III et al. | Apr 2001 | B1 |
| 6224592 | Eggers et al. | May 2001 | B1 |
| 6238387 | Miller, III | May 2001 | B1 |
| 6245065 | Panescu et al. | Jun 2001 | B1 |
| 6246912 | Sluijter et al. | Jun 2001 | B1 |
| 6262695 | McGowan | Jul 2001 | B1 |
| 6273886 | Edwards | Aug 2001 | B1 |
| 6283951 | Flaherty et al. | Sep 2001 | B1 |
| 6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
| 6293941 | Strul et al. | Sep 2001 | B1 |
| 6314325 | Fitz | Nov 2001 | B1 |
| 6322558 | Taylor et al. | Nov 2001 | B1 |
| 6322559 | Daulton et al. | Nov 2001 | B1 |
| 6358246 | Behl et al. | Mar 2002 | B1 |
| 6405732 | Edwards et al. | Jun 2002 | B1 |
| 6413255 | Stern | Jul 2002 | B1 |
| 6423057 | He et al. | Jul 2002 | B1 |
| 6428537 | Swanson et al. | Aug 2002 | B1 |
| 6451015 | Rittman, III et al. | Sep 2002 | B1 |
| 6464696 | Oyama et al. | Oct 2002 | B1 |
| 6488678 | Sherman | Dec 2002 | B2 |
| 6488679 | Swanson et al. | Dec 2002 | B1 |
| 6494880 | Swanson et al. | Dec 2002 | B1 |
| 6500172 | Panescu et al. | Dec 2002 | B1 |
| 6506189 | Rittman, III et al. | Jan 2003 | B1 |
| 6508815 | Strul et al. | Jan 2003 | B1 |
| 6511476 | Hareyama | Jan 2003 | B2 |
| 6514226 | Levin et al. | Feb 2003 | B1 |
| 6514248 | Eggers et al. | Feb 2003 | B1 |
| 6522926 | Kieval et al. | Feb 2003 | B1 |
| 6542781 | Koblish et al. | Apr 2003 | B1 |
| 6558378 | Sherman et al. | May 2003 | B2 |
| 6562034 | Edwards et al. | May 2003 | B2 |
| 6616624 | Kieval | Sep 2003 | B1 |
| 6622731 | Daniel et al. | Sep 2003 | B2 |
| 6635054 | Fjield et al. | Oct 2003 | B2 |
| 6635057 | Harano et al. | Oct 2003 | B2 |
| 6640120 | Swanson et al. | Oct 2003 | B1 |
| 6648883 | Francischelli et al. | Nov 2003 | B2 |
| 6666862 | Jain et al. | Dec 2003 | B2 |
| 6679269 | Swanson | Jan 2004 | B2 |
| 6682527 | Strul | Jan 2004 | B2 |
| 6685648 | Flaherty et al. | Feb 2004 | B2 |
| 6685700 | Behl et al. | Feb 2004 | B2 |
| 6711444 | Koblish | Mar 2004 | B2 |
| 6730079 | Lovewell | May 2004 | B2 |
| 6733498 | Paton et al. | May 2004 | B2 |
| 6736835 | Pellegrino et al. | May 2004 | B2 |
| 6752804 | Simpson et al. | Jun 2004 | B2 |
| 6761716 | Kadhiresan et al. | Jul 2004 | B2 |
| 6845267 | Harrison et al. | Jan 2005 | B2 |
| 6849073 | Hoey et al. | Feb 2005 | B2 |
| 6850801 | Kieval et al. | Feb 2005 | B2 |
| 6855141 | Lovewell | Feb 2005 | B2 |
| 6855142 | Harano et al. | Feb 2005 | B2 |
| 6885888 | Rezai | Apr 2005 | B2 |
| 6893436 | Woodard et al. | May 2005 | B2 |
| 6917834 | Koblish et al. | Jul 2005 | B2 |
| 6923808 | Taimisto | Aug 2005 | B2 |
| 6936047 | Nasab et al. | Aug 2005 | B2 |
| 6939346 | Kannenberg et al. | Sep 2005 | B2 |
| 6949097 | Stewart et al. | Sep 2005 | B2 |
| 6955675 | Jain | Oct 2005 | B2 |
| 6989010 | Francischelli et al. | Jan 2006 | B2 |
| 7001379 | Behl et al. | Feb 2006 | B2 |
| 7001381 | Harano et al. | Feb 2006 | B2 |
| 7008417 | Eick | Mar 2006 | B2 |
| 7025764 | Paton et al. | Apr 2006 | B2 |
| 7029470 | Francischelli et al. | Apr 2006 | B2 |
| 7066933 | Hagg | Jun 2006 | B2 |
| 7076399 | Godara | Jul 2006 | B2 |
| 7104985 | Martinelli | Sep 2006 | B2 |
| 7108694 | Miura et al. | Sep 2006 | B2 |
| 7131445 | Amoah | Nov 2006 | B2 |
| 7149574 | Yun et al. | Dec 2006 | B2 |
| 7160296 | Pearson et al. | Jan 2007 | B2 |
| 7162303 | Levin et al. | Jan 2007 | B2 |
| 7169144 | Hoey et al. | Jan 2007 | B2 |
| 7221979 | Zhou et al. | May 2007 | B2 |
| 7226447 | Uchida et al. | Jun 2007 | B2 |
| 7247155 | Hoey et al. | Jul 2007 | B2 |
| 7250048 | Francischelli et al. | Jul 2007 | B2 |
| 7258688 | Shah et al. | Aug 2007 | B1 |
| 7364578 | Francischelli et al. | Apr 2008 | B2 |
| 7367972 | Francischelli et al. | May 2008 | B2 |
| 7381200 | Katoh et al. | Jun 2008 | B2 |
| 7390894 | Weinshilboum et al. | Jun 2008 | B2 |
| 7429261 | Kunis et al. | Sep 2008 | B2 |
| 7533002 | Godara | May 2009 | B2 |
| 7582084 | Swanson et al. | Sep 2009 | B2 |
| 7596469 | Godara | Sep 2009 | B2 |
| 7617005 | Demarais et al. | Nov 2009 | B2 |
| 7647115 | Levin et al. | Jan 2010 | B2 |
| 7651492 | Wham | Jan 2010 | B2 |
| 7653438 | Deem et al. | Jan 2010 | B2 |
| 7717909 | Strul et al. | May 2010 | B2 |
| 7717948 | Demarais et al. | May 2010 | B2 |
| 7778703 | Gross et al. | Aug 2010 | B2 |
| 7792589 | Levy, Jr. et al. | Sep 2010 | B2 |
| 7799020 | Shores et al. | Sep 2010 | B2 |
| 7824399 | Francischelli et al. | Nov 2010 | B2 |
| 7837679 | Biggs et al. | Nov 2010 | B2 |
| 7842076 | Zikorus et al. | Nov 2010 | B2 |
| 7846160 | Payne et al. | Dec 2010 | B2 |
| 7887534 | Hamel et al. | Feb 2011 | B2 |
| 7901400 | Wham et al. | Mar 2011 | B2 |
| 7922714 | Stevens-Wright | Apr 2011 | B2 |
| 7927328 | Orszulak et al. | Apr 2011 | B2 |
| 7959626 | Hong et al. | Jun 2011 | B2 |
| 7963962 | Thompson et al. | Jun 2011 | B2 |
| 7972328 | Wham et al. | Jul 2011 | B2 |
| 7976540 | Daw et al. | Jul 2011 | B2 |
| 8048070 | O'Brien et al. | Nov 2011 | B2 |
| 8058771 | Giordano et al. | Nov 2011 | B2 |
| 8080008 | Wham et al. | Dec 2011 | B2 |
| 8086315 | Schwartz et al. | Dec 2011 | B2 |
| 8095212 | Sato | Jan 2012 | B2 |
| 8105323 | Buysse et al. | Jan 2012 | B2 |
| 8131371 | Demarais et al. | Mar 2012 | B2 |
| 8131372 | Levin et al. | Mar 2012 | B2 |
| 8140170 | Rezai et al. | Mar 2012 | B2 |
| 8145317 | Demarais et al. | Mar 2012 | B2 |
| 8147485 | Wham et al. | Apr 2012 | B2 |
| 8150518 | Levin et al. | Apr 2012 | B2 |
| 8150519 | Demarais et al. | Apr 2012 | B2 |
| 8150520 | Demarais et al. | Apr 2012 | B2 |
| 8152801 | Goldberg et al. | Apr 2012 | B2 |
| 8152802 | Podhajsky et al. | Apr 2012 | B2 |
| 8162932 | Podhajsky et al. | Apr 2012 | B2 |
| 8175711 | Demarais et al. | May 2012 | B2 |
| 8241275 | Hong et al. | Aug 2012 | B2 |
| 8273084 | Kunis et al. | Sep 2012 | B2 |
| 8340763 | Levin et al. | Dec 2012 | B2 |
| 8702619 | Wang | Apr 2014 | B2 |
| 8768470 | Deem et al. | Jul 2014 | B2 |
| 8876813 | Min et al. | Nov 2014 | B2 |
| 8909316 | Ng | Dec 2014 | B2 |
| 8977359 | Rossing | Mar 2015 | B2 |
| 9002446 | Wenzel et al. | Apr 2015 | B2 |
| 9014809 | Wenzel et al. | Apr 2015 | B2 |
| 9014821 | Wang | Apr 2015 | B2 |
| 9022948 | Wang | May 2015 | B2 |
| 9028472 | Mathur et al. | May 2015 | B2 |
| 9037259 | Mathur | May 2015 | B2 |
| 9043191 | Grady et al. | May 2015 | B2 |
| 9119600 | Richardson et al. | Sep 2015 | B2 |
| 9168094 | Lee et al. | Oct 2015 | B2 |
| 9179973 | Nabutovsky et al. | Nov 2015 | B2 |
| 9186212 | Nabutovsky et al. | Nov 2015 | B2 |
| 9295842 | Ghaffari et al. | Mar 2016 | B2 |
| 9314300 | Nabutovsky et al. | Apr 2016 | B2 |
| 9375154 | Wang | Jun 2016 | B2 |
| 9427283 | Nabutovsky et al. | Aug 2016 | B2 |
| 9427579 | Fain et al. | Aug 2016 | B2 |
| 9554850 | Lee et al. | Jan 2017 | B2 |
| 9561070 | Brotz et al. | Feb 2017 | B2 |
| 9579030 | Scheuermann et al. | Feb 2017 | B2 |
| 20010014802 | Tu | Aug 2001 | A1 |
| 20020091385 | Paton et al. | Jul 2002 | A1 |
| 20020139379 | Edwards et al. | Oct 2002 | A1 |
| 20020161422 | Swanson | Oct 2002 | A1 |
| 20020165532 | Hill et al. | Nov 2002 | A1 |
| 20020183682 | Darvish et al. | Dec 2002 | A1 |
| 20030050635 | Truckai et al. | Mar 2003 | A1 |
| 20030050681 | Pianca et al. | Mar 2003 | A1 |
| 20030060858 | Kieval et al. | Mar 2003 | A1 |
| 20030065322 | Panescu et al. | Apr 2003 | A1 |
| 20030074039 | Puskas | Apr 2003 | A1 |
| 20030125790 | Fastovsky et al. | Jul 2003 | A1 |
| 20030181897 | Thomas et al. | Sep 2003 | A1 |
| 20030199863 | Swanson et al. | Oct 2003 | A1 |
| 20030216792 | Levin et al. | Nov 2003 | A1 |
| 20030229340 | Sherry et al. | Dec 2003 | A1 |
| 20030233099 | Danaek et al. | Dec 2003 | A1 |
| 20040010289 | Biggs et al. | Jan 2004 | A1 |
| 20040068304 | Paton et al. | Apr 2004 | A1 |
| 20040122420 | Amoah | Jun 2004 | A1 |
| 20040215186 | Cornelius et al. | Oct 2004 | A1 |
| 20050021020 | Blaha | Jan 2005 | A1 |
| 20050080409 | Young et al. | Apr 2005 | A1 |
| 20050096647 | Steinke et al. | May 2005 | A1 |
| 20050187579 | Danek et al. | Aug 2005 | A1 |
| 20050228460 | Levin et al. | Oct 2005 | A1 |
| 20050283148 | Janssen et al. | Dec 2005 | A1 |
| 20060085054 | Zikorus et al. | Apr 2006 | A1 |
| 20060095029 | Young et al. | May 2006 | A1 |
| 20060100618 | Chan et al. | May 2006 | A1 |
| 20060106375 | Werneth et al. | May 2006 | A1 |
| 20060142753 | Francischelli et al. | Jun 2006 | A1 |
| 20060161148 | Behnke | Jul 2006 | A1 |
| 20060206150 | Demarais et al. | Sep 2006 | A1 |
| 20060271111 | Demarais et al. | Nov 2006 | A1 |
| 20070016274 | Boveja et al. | Jan 2007 | A1 |
| 20070083193 | Werneth et al. | Apr 2007 | A1 |
| 20070083195 | Werneth et al. | Apr 2007 | A1 |
| 20070100390 | Danaek | May 2007 | A1 |
| 20070112342 | Pearson et al. | May 2007 | A1 |
| 20070129720 | Demarais et al. | Jun 2007 | A1 |
| 20070167943 | Janssen et al. | Jul 2007 | A1 |
| 20070203481 | Gregg et al. | Aug 2007 | A1 |
| 20070208333 | Uchida et al. | Sep 2007 | A1 |
| 20070265687 | Deem et al. | Nov 2007 | A1 |
| 20070270795 | Francischelli et al. | Nov 2007 | A1 |
| 20080015562 | Hong et al. | Jan 2008 | A1 |
| 20080071257 | Kotmel et al. | Mar 2008 | A1 |
| 20080077126 | Rashidi | Mar 2008 | A1 |
| 20080101356 | Babbar et al. | May 2008 | A1 |
| 20080147057 | Eisele | Jun 2008 | A1 |
| 20080188912 | Stone et al. | Aug 2008 | A1 |
| 20080188913 | Stone et al. | Aug 2008 | A1 |
| 20080228181 | Godara et al. | Sep 2008 | A1 |
| 20080255539 | Booth | Oct 2008 | A1 |
| 20080262489 | Steinke | Oct 2008 | A1 |
| 20080281312 | Werneth et al. | Nov 2008 | A1 |
| 20080281322 | Sherman et al. | Nov 2008 | A1 |
| 20080300589 | Paul et al. | Dec 2008 | A1 |
| 20080319513 | Pu et al. | Dec 2008 | A1 |
| 20090030477 | Jarrard | Jan 2009 | A1 |
| 20090036948 | Levin et al. | Feb 2009 | A1 |
| 20090182323 | Eder et al. | Jul 2009 | A1 |
| 20090182325 | Werneth et al. | Jul 2009 | A1 |
| 20090299365 | Stewart et al. | Dec 2009 | A1 |
| 20100137860 | Demarais et al. | Jun 2010 | A1 |
| 20100137952 | Demarais et al. | Jun 2010 | A1 |
| 20100179533 | Podhajsky | Jul 2010 | A1 |
| 20100179538 | Podhajsky | Jul 2010 | A1 |
| 20100191112 | Demarais et al. | Jul 2010 | A1 |
| 20100211063 | Wham et al. | Aug 2010 | A1 |
| 20100222851 | Deem et al. | Sep 2010 | A1 |
| 20100222854 | Demarais et al. | Sep 2010 | A1 |
| 20100228247 | Paul et al. | Sep 2010 | A1 |
| 20100324548 | Godara et al. | Dec 2010 | A1 |
| 20110077641 | Dunning | Mar 2011 | A1 |
| 20110087214 | Giordano et al. | Apr 2011 | A1 |
| 20110087217 | Yates et al. | Apr 2011 | A1 |
| 20110112400 | Emery et al. | May 2011 | A1 |
| 20110130755 | Bhushan et al. | Jun 2011 | A1 |
| 20110190755 | Mathur et al. | Aug 2011 | A1 |
| 20110230876 | Hong et al. | Sep 2011 | A1 |
| 20110264086 | Ingle | Oct 2011 | A1 |
| 20110270120 | McFarlin et al. | Nov 2011 | A1 |
| 20110270237 | Werneth et al. | Nov 2011 | A1 |
| 20110270247 | Sherman | Nov 2011 | A1 |
| 20110306851 | Wang | Dec 2011 | A1 |
| 20120029504 | Afonso et al. | Feb 2012 | A1 |
| 20120041502 | Schwartz et al. | Feb 2012 | A1 |
| 20120095461 | Herscher et al. | Apr 2012 | A1 |
| 20120101413 | Beetel | Apr 2012 | A1 |
| 20120101538 | Ballakur et al. | Apr 2012 | A1 |
| 20120123400 | Francischelli et al. | May 2012 | A1 |
| 20120130289 | Demarais et al. | May 2012 | A1 |
| 20120130345 | Levin et al. | May 2012 | A1 |
| 20120136346 | Condie et al. | May 2012 | A1 |
| 20120136348 | Condie et al. | May 2012 | A1 |
| 20120136350 | Goshgarian et al. | May 2012 | A1 |
| 20120143097 | Pike, Jr. | Jun 2012 | A1 |
| 20120143293 | Mauch et al. | Jun 2012 | A1 |
| 20120150169 | Zielinksi et al. | Jun 2012 | A1 |
| 20120172837 | Demarais et al. | Jul 2012 | A1 |
| 20120172870 | Jenson et al. | Jul 2012 | A1 |
| 20120191079 | Moll et al. | Jul 2012 | A1 |
| 20120197243 | Sherman et al. | Aug 2012 | A1 |
| 20120197246 | Mauch | Aug 2012 | A1 |
| 20120296232 | Ng | Nov 2012 | A1 |
| 20120296329 | Ng | Nov 2012 | A1 |
| 20120310241 | Orszulak | Dec 2012 | A1 |
| 20130006228 | Johnson et al. | Jan 2013 | A1 |
| 20130006235 | Podhajsky et al. | Jan 2013 | A1 |
| 20130085489 | Fain et al. | Apr 2013 | A1 |
| 20130123778 | Richardson et al. | May 2013 | A1 |
| 20130165764 | Scheuermann et al. | Jun 2013 | A1 |
| 20130172878 | Smith | Jul 2013 | A1 |
| 20130218029 | Cholette et al. | Aug 2013 | A1 |
| 20130231659 | Hill et al. | Sep 2013 | A1 |
| 20130274614 | Shimada et al. | Oct 2013 | A1 |
| 20130282001 | Hezi-Yamit et al. | Oct 2013 | A1 |
| 20130296840 | Condie | Nov 2013 | A1 |
| 20140012133 | Sverdlik et al. | Jan 2014 | A1 |
| 20140025069 | Willard et al. | Jan 2014 | A1 |
| 20140066803 | Choi | Mar 2014 | A1 |
| 20140073903 | Weber et al. | Mar 2014 | A1 |
| 20140074089 | Nishii | Mar 2014 | A1 |
| 20140128865 | Gross | May 2014 | A1 |
| 20140194866 | Wang | Jul 2014 | A1 |
| 20140213873 | Wang | Jul 2014 | A1 |
| 20140221805 | Wang | Aug 2014 | A1 |
| 20140228614 | Stopek | Aug 2014 | A1 |
| 20140228829 | Schmitt et al. | Aug 2014 | A1 |
| 20140228858 | Stopek | Aug 2014 | A1 |
| 20140236137 | Tran et al. | Aug 2014 | A1 |
| 20140236138 | Tran et al. | Aug 2014 | A1 |
| 20140246465 | Peterson et al. | Sep 2014 | A1 |
| 20140249524 | Kocur | Sep 2014 | A1 |
| 20140257266 | Kasprzyk et al. | Sep 2014 | A1 |
| 20140266235 | Mathur | Sep 2014 | A1 |
| 20140275924 | Min et al. | Sep 2014 | A1 |
| 20140276124 | Cholette et al. | Sep 2014 | A1 |
| 20140276718 | Turovskiy | Sep 2014 | A1 |
| 20140276733 | VanScoy et al. | Sep 2014 | A1 |
| 20140276742 | Nabutovsky et al. | Sep 2014 | A1 |
| 20140276746 | Nabutovsky et al. | Sep 2014 | A1 |
| 20140276755 | Cao et al. | Sep 2014 | A1 |
| 20140276762 | Parsonage | Sep 2014 | A1 |
| 20140276766 | Brotz et al. | Sep 2014 | A1 |
| 20140276767 | Brotz et al. | Sep 2014 | A1 |
| 20140276773 | Brotz et al. | Sep 2014 | A1 |
| 20140316400 | Blix et al. | Oct 2014 | A1 |
| 20140316496 | Masson et al. | Oct 2014 | A1 |
| 20140330266 | Thompson et al. | Nov 2014 | A1 |
| 20140330267 | Harrington | Nov 2014 | A1 |
| 20140336637 | Agrawal et al. | Nov 2014 | A1 |
| 20150005764 | Hanson et al. | Jan 2015 | A1 |
| 20150018656 | Min et al. | Jan 2015 | A1 |
| 20150025524 | Nabutovsky | Jan 2015 | A1 |
| 20150112329 | Ng | Apr 2015 | A1 |
| 20150119674 | Fischell et al. | Apr 2015 | A1 |
| 20150173673 | Toth et al. | Jun 2015 | A1 |
| 20150201997 | Osypka | Jul 2015 | A1 |
| 20150216590 | Wang et al. | Aug 2015 | A1 |
| 20150223877 | Behar et al. | Aug 2015 | A1 |
| 20150224326 | Toth et al. | Aug 2015 | A1 |
| 20150245867 | Gross | Sep 2015 | A1 |
| 20150289929 | Toth et al. | Oct 2015 | A1 |
| 20150366609 | Richardson et al. | Dec 2015 | A1 |
| 20160000345 | Kobayashi et al. | Jan 2016 | A1 |
| 20160029960 | Toth et al. | Feb 2016 | A1 |
| 20160038028 | Buelna et al. | Feb 2016 | A1 |
| 20160081744 | Wang | Mar 2016 | A1 |
| 20160106498 | Highsmith et al. | Apr 2016 | A1 |
| 20160184010 | Nabutovsky et al. | Jun 2016 | A1 |
| 20160213262 | Ghaffari et al. | Jul 2016 | A1 |
| 20160213424 | Ghaffari et al. | Jul 2016 | A1 |
| 20160310201 | Brotz et al. | Oct 2016 | A1 |
| 20160324572 | Gross et al. | Nov 2016 | A1 |
| 20160331451 | Nabutovsky et al. | Nov 2016 | A1 |
| 20160331453 | Fain et al. | Nov 2016 | A1 |
| 20160374568 | Wang | Dec 2016 | A1 |
| 20170007157 | Gross et al. | Jan 2017 | A1 |
| 20170007158 | Gross et al. | Jan 2017 | A1 |
| 20170215950 | Gross et al. | Aug 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 0768841 | Apr 1997 | EP |
| 1169976 | Jan 2002 | EP |
| 1366724 | Dec 2003 | EP |
| 2316371 | May 2011 | EP |
| 2460486 | Jun 2012 | EP |
| 2594193 | May 2013 | EP |
| 2613704 | Jul 2013 | EP |
| 2747691 | Jul 2014 | EP |
| 2797535 | Nov 2014 | EP |
| 2852339 | Apr 2015 | EP |
| 2866645 | May 2015 | EP |
| 2887900 | Jul 2015 | EP |
| 2907464 | Aug 2015 | EP |
| 2914192 | Sep 2015 | EP |
| 2914334 | Sep 2015 | EP |
| 2967383 | Jan 2016 | EP |
| 2967702 | Jan 2016 | EP |
| 2967703 | Jan 2016 | EP |
| 2967728 | Jan 2016 | EP |
| 2967729 | Jan 2016 | EP |
| 2967733 | Jan 2016 | EP |
| 2968931 | Jan 2016 | EP |
| 2978372 | Feb 2016 | EP |
| 2991575 | Mar 2016 | EP |
| 3011899 | Apr 2016 | EP |
| 3028628 | Jun 2016 | EP |
| 3089686 | Nov 2016 | EP |
| 3158961 | Apr 2017 | EP |
| H08504531 | May 1996 | JP |
| H1071037 | Mar 1998 | JP |
| 2001518808 | Oct 2001 | JP |
| 2005278739 | Oct 2005 | JP |
| 2008515544 | May 2008 | JP |
| 2009539565 | Nov 2009 | JP |
| 2010162163 | Jul 2010 | JP |
| 2010533513 | Oct 2010 | JP |
| 2011505929 | Mar 2011 | JP |
| 6122206 | Apr 2017 | JP |
| WO-2014091328 | Jul 1989 | WO |
| WO-9308757 | May 1993 | WO |
| 1994007446 | Apr 1994 | WO |
| WO-9410922 | May 1994 | WO |
| WO-1995025472 | Sep 1995 | WO |
| 1995031142 | Nov 1995 | WO |
| WO-9600036 | Jan 1996 | WO |
| WO-9639086 | Dec 1996 | WO |
| WO-9704702 | Feb 1997 | WO |
| WO-1997036548 | Oct 1997 | WO |
| WO-9740882 | Nov 1997 | WO |
| 1998042403 | Oct 1998 | WO |
| 1999000060 | Jan 1999 | WO |
| WO-9900060 | Jan 1999 | WO |
| WO-9960923 | Dec 1999 | WO |
| WO-00001313 | Jan 2000 | WO |
| WO-00001313 | Jan 2000 | WO |
| WO-0015130 | Mar 2000 | WO |
| WO-0119270 | Mar 2001 | WO |
| WO-0119270 | Mar 2001 | WO |
| WO-0122897 | Apr 2001 | WO |
| WO-2001022897 | Apr 2001 | WO |
| WO-2001070114 | Sep 2001 | WO |
| WO-02087679 | Nov 2002 | WO |
| WO-02087679 | Nov 2002 | WO |
| 2003022167 | Mar 2003 | WO |
| 2003082080 | Oct 2003 | WO |
| WO-2005030072 | Apr 2005 | WO |
| WO-2005041748 | May 2005 | WO |
| WO-2005051215 | Jun 2005 | WO |
| WO-2005110528 | Nov 2005 | WO |
| WO-2006041881 | Apr 2006 | WO |
| WO-2006080982 | Aug 2006 | WO |
| 2006105121 | Oct 2006 | WO |
| WO-2007001981 | Jan 2007 | WO |
| WO-2007001981 | Jan 2007 | WO |
| WO-2007008954 | Jan 2007 | WO |
| WO-2007067941 | Jun 2007 | WO |
| 2007078997 | Jul 2007 | WO |
| WO-2007135431 | Nov 2007 | WO |
| WO-2007135431 | Nov 2007 | WO |
| WO-2008003058 | Jan 2008 | WO |
| 2008049084 | Apr 2008 | WO |
| WO-2008101356 | Aug 2008 | WO |
| WO-2010078175 | Jul 2010 | WO |
| WO-2011017168 | Feb 2011 | WO |
| WO-2011089935 | Jul 2011 | WO |
| WO-2011126580 | Oct 2011 | WO |
| WO-2011144911 | Nov 2011 | WO |
| WO-2012024631 | Feb 2012 | WO |
| WO-2012033974 | Mar 2012 | WO |
| WO-2012054762 | Apr 2012 | WO |
| WO-2012068471 | May 2012 | WO |
| WO-2012158864 | Nov 2012 | WO |
| WO-2013030738 | Mar 2013 | WO |
| WO-2013030743 | Mar 2013 | WO |
| WO-2013074813 | May 2013 | WO |
| WO-2013101485 | Jul 2013 | WO |
| WO-2013112844 | Aug 2013 | WO |
| WO-2014012282 | Jan 2014 | WO |
| WO-2014029355 | Feb 2014 | WO |
| WO-2014059165 | Apr 2014 | WO |
| WO-2014068577 | May 2014 | WO |
| WO-2014091401 | Jun 2014 | WO |
| WO-2014124241 | Aug 2014 | WO |
| WO-2014149550 | Sep 2014 | WO |
| WO-2014149552 | Sep 2014 | WO |
| WO-2014149553 | Sep 2014 | WO |
| WO-2014149690 | Sep 2014 | WO |
| WO-2014150425 | Sep 2014 | WO |
| WO-2014150432 | Sep 2014 | WO |
| WO-2014150441 | Sep 2014 | WO |
| WO-2014150455 | Sep 2014 | WO |
| WO-2014158708 | Oct 2014 | WO |
| WO-2014158713 | Oct 2014 | WO |
| WO-2014163990 | Oct 2014 | WO |
| WO-2014179110 | Nov 2014 | WO |
| WO-2014179768 | Nov 2014 | WO |
| WO-2014182946 | Nov 2014 | WO |
| Entry |
|---|
| Ahmed, Humera et al., Renal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension, JACC Cardiovascular Interventions, vol. 5, No. 7, 2012, pp. 758-765. |
| Avitall et al., “The creation of linear contiguous lesions in the atria with an expandable loop catheter,” Journal of the American College of Cardiology, 1999; 33; pp. 972-984. |
| Beale et al., “Minimally Invasive Treatment for Varicose Veins: A Review of Endovenous Laser Treatment and Radiofrequency Ablation”. Lower Extremity Wounds 3(4), 2004, 10 pages. |
| Blessing, Erwin et al., Cardiac Ablation and Renal Denervation Systems Have Distinct Purposes and Different Technical Requirements, JACC Cardiovascular Interventions, vol. 6, No. 3, 2013, 1 page. |
| ClinicalTrials.gov, Renal Denervation in Patients with uncontrolled Hypertension in Chinese (2011), 6pages. www.clinicaltrials.gov/ct2/show/NCT01390831. |
| Excerpt of Operator's Manual of Boston Scientific's EPT-1000 XP Cardiac Ablation Controller & Accessories, Version of Apr. 2003, (6 pages). |
| Excerpt of Operator's Manual of Boston Scientific's Maestro 30000 Cardiac Ablation System, Version of Oct. 17, 2005 , (4 pages). |
| Holmes et al., Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation: Clinical Spectrum and Interventional Considerations, JACC: Cardiovascular Interventions, 2: 4, 2009, 10 pages. |
| Kandarpa, Krishna et al., “Handbook of Interventional Radiologic Procedures”, Third Edition, pp. 194-210 (2002). |
| Mount Sinai School of Medicine clinical trial for Impact of Renal Sympathetic Denervation of Chronic Hypertension, Mar. 2013, 11 pages. http://clinicaltrials.gov/ct2/show/NCT01628198. |
| Opposition to European Patent No. EP1802370, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 20 pages. |
| Opposition to European Patent No. EP2037840, Granted Dec. 7, 2011, Date of Opposition Sep. 7, 2012, 25 pages. |
| Opposition to European Patent No. EP2092957, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 26 pages. |
| Oz, Mehmet, Pressure Relief, Time, Jan. 9, 2012, 2 pages. <www.time.come/time/printout/0,8816,2103278,00.html>. |
| Papademetriou, Vasilios, Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension, Int. Journal of Hypertension, 2011, 8 pages. |
| Prochnau, Dirk et al., Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter; Euro Intervention 2012, vol. 7, pp. 1077-1080. |
| Purerfellner, Helmut et al., Incidence, Management, and Outcome in Significant Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation, Am. J. Cardiol , 93, Jun. 1, 2004, 4 pages. |
| Purerfellner, Helmut et al., Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation, Curr. Opin. Cardio. 20 :484-490, 2005. |
| Schneider, Peter A., “Endovascular Skills—Guidewire and Catheter Skills for Endovascular Surgery,” Second Edition Revised and Expanded, 10 pages, (2003). |
| ThermoCool Irrigated Catheter and Integrated Ablation System, Biosense Webster (2006), 6 pages. |
| Tsao, Hsuan-Ming, Evaluation of Pulmonary Vein Stenosis after Catheter Ablation of Atrial Fibrillation, Cardiac Electrophysiology Review, 6, 2002, 4 pages. |
| Wittkampf et al., “Control of radiofrequency lesion size by power regulation,” Journal of the American Heart Associate, 1989, 80: pp. 962-968. |
| Zheng et al., “Comparison of the temperature profile and pathological effect at unipolar, bipolar and phased radiofrequency current configurations,” Journal of Interventional Cardiac Electrophysiology, 2001, pp. 401-410. |
| European Search Report for European Application No. 13159256, dated Oct. 17, 2013, 6 pages. |
| Allen, E.V., Sympathectomy for essential hypertension, Circulation, 1952, 6:131-140. |
| Bello-Reuss, E. et al., “Effects of Acute Unilateral Renal Denervation in the Rat,” Journal of Clinical Investigation, vol. 56, Jul. 1975, pp. 208-217. |
| Bello-Reuss, E. et al., “Effects of Renal Sympathetic Nerve Stimulation on Proximal Water and Sodium Reabsorption,” Journal of Clinical Investigation, vol. 57, Apr. 1976, pp. 1104-1107. |
| Bhandari, A. and Ellias, M., “Loin Pain Hematuria Syndrome: Pain Control with RFA to the Splanchanic Plexus,” The Pain Clinc, 2000, vol. 12, No. 4, pp. 323-327. |
| Curtis, John J. et al., “Surgical Therapy for Persistent Hypertension After Renal Transplantation” Transplantation, 31:125-128 (1981). |
| Dibona, Gerald F. et al., “Neural Control of Renal Function,” Physiological Reviews, vol. 77, No. 1, Jan. 1997, The American Physiological Society 1997, pp. 75-197. |
| Dibona, Gerald F., “Neural Control of the Kidney—Past, Present and Future,” Nov. 4, 2002, Novartis Lecture, Hypertension 2003, 41 part 2, 2002 American Heart Association, Inc., pp. 621-624. |
| Janssen, Ben J.A. et al., “Effects of Complete Renal Denervation and Selective Afferent Renal Denervation on the Hypertension Induced by Intrarenal Norepinephrine Infusion in Conscious Rats”, Journal of Hypertension 1989, 7: 447-455. |
| Katholi, Richard E., “Renal Nerves in the Pathogenesis of Hypertension in Experimental Animals and Humans,” Am J. Physiol. vol. 245, 1983, the American Physiological Society 1983, pp. F1-F14. |
| Krum, Henry et al., “Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Mulitcentre Safety and Proof-of Principle Cohort Study,” Lancet 2009; 373:1275-81. |
| Krum, et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension.” New England Journal of Med, Aug. 2009, 361; 9, 3 pages. |
| Luippold, Gerd et al., “Chronic Renal Denervation Prevents Glomerular Hyperfiltration in Diabetic Rats”, Nephrol Dial Transplant, vol. 19, No. 2, 2004, pp. 342-347. |
| Mahfoud et al. “Treatment strategies for resistant arterial hypertension” Dtsch Arztebl Int. 2011;108:725-731. |
| Osborn, et al., “Effect of Renal Nerve Stimulation on Renal Blood Flow Autoregulation and Antinatriuresis During Reductions in Renal Perfusion Pressure,” Proceedings of the Society for Experimental Biology and Medicine, vol. 168, 77-81, 1981. |
| Page, I.H. et al., “The Effect of Renal Denervation on Patients Suffering From Nephritis,” Feb. 27, 1935;443-458. |
| Page, I.H. et al., “The Effect of Renal Denervation on the Level of Arterial Blood Pressure and Renal Function in Essential Hypertension,” J. Clin Invest. 1934;14:27-30. |
| Rocha-Singh, “Catheter-Based Sympathetic Renal Denervation,” Endovascular Today, Aug. 2009, 4 pages. |
| Schlaich, M.P. et al., “Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept,” Hypertension, 2009; 54:1195-1201. |
| Schlaich, M.P. et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension,” N Engl J Med 2009; 361(9): 932-934. |
| Smithwick, R.H. et al., “Splanchnicectomy for Essential Hypertension,” Journal Am Med Assn, 1953; 152:1501-1504. |
| Symplicity HTN-1 Investigators; Krum H, Barman N, Schlaich M, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-917. |
| Symplicity HTN-2 Investigators, “Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial”; Lancet, Dec. 4, 2010, vol. 376, pp. 1903-1909. |
| United States Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003, 593 pages. |
| Valente, John F. et al., “Laparoscopic Renal Denervation for Intractable ADPKD-Related Pain”, Nephrol Dial Transplant (2001) 16: 1 page. |
| Wagner, C.D. et al., “Very Low Frequency Oscillations in Arterial Blood Pressure After Autonomic Blockade in Conscious Dogs,” Feb. 5, 1997, Am J Physiol Regul Integr Comp Physiol 1997, vol. 272, 1997 the American Physiological Society, pp. 2034-2039. |
| U.S. Appl. No. 95/002,110, filed Aug. 29, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,209, filed Sep. 13, 2012, Levin et al. |
| U.S. Appl. No. 95/002,233, filed Sep. 13, 2012, Levin et al. |
| U.S. Appl. No. 95/002,243, filed Sep. 13, 2012, Levin et al. |
| U.S. Appl. No. 95/002,253, filed Sep. 13, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,255, filed Sep. 13, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,292, filed Sep. 14, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,327, filed Sep. 14, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,335, filed Sep. 14, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,336, filed Sep. 14, 2012, Levin et al. |
| U.S. Appl. No. 95/002,356, filed Sep. 14, 2012, Demarais et al. |
| “2011 Edison Award Winners.” Edison Awards: Honoring Innovations & Innovators, 2011, 6 pages, <http://www.edisonawards.com/BestNewProduct_2011.php>. |
| “2012 top 10 advances in heart disease and stroke research: American Heart Association/America Stroke Association Top 10 Research Report.” American Heart Association, Dec. 17, 2012, 5 pages, <http://newsroom.heart.org/news/2012-top-10-advances-in-heart-241901>. |
| “Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension.” PR Newswire, Jun. 3, 2010, 2 pages, <http://www.prnewswire.com/news-releases/ardianr-receives-2010-europcr-innovation-award-and-demonstrates-further-durability-of-renal-denervation-treatment-for-hypertension-95545014.html>. |
| “Boston Scientific to Acquire Vessix Vascular, Inc.: Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology.” Boston Scientific: Advancing science for life—Investor Relations, Nov. 8, 2012, 2 pages, <http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-newsArticle&id=1756108>. |
| “Cleveland Clinic Unveils Top 10 Medical Innovations for 2012: Experts Predict Ten Emerging Technologies that will Shape Health Care Next Year.” Cleveland Clinic, Oct. 6, 2011, 2 pages. <http://my.clevelandclinic.org/media_relations/library/2011/2011-10-6-cleveland-clinic-unveils-top-10-medical-innovations-for-2012.aspx>. |
| “Does renal denervation represent a new treatment option for resistant hypertension?” Interventional News, Aug. 3, 2010, 2 pages. <http://www.cxvascular.com/in-latest-news/interventional-news---latest-news/does-renal-denervation-represent-a-new-treatment-option-for-resistant-hypertension>. |
| “Iberis—Renal Sympathetic Denervation System: Turning innovation into quality care.” [Brochure], Terumo Europe N.V., 2013, Europe, 3 pages. |
| “Neurotech Reports Announces Winners of Gold Electrode Awards.” Neurotech business report, 2009. 1 page. <http://www.neurotechreports.com/pages/goldelectrodes09.html>. |
| “Quick. Consistent. Controlled. OneShot renal Denervation System” [Brochure], Covidien: positive results for life, 2013, (n.l.), 4 pages. |
| “Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million.” Vessix Vascular Pharmaceutical Intelligence: A blog specializing in Pharmaceutical Intelligence and Analytics, Nov. 8, 2012, 21 pages, <http://pharmaceuticalintelligence.com/tag/vessix-vascular/>. |
| “The Edison Awards™” Edison Awards: Honoring Innovations & Innovators, 2013, 2 pages, <http://www.edisonawards.com/Awards.php>. |
| “The Future of Renal denervation for the Treatment of Resistant Hypertension.” St. Jude Medical, Inc., 2012, 12 pages. |
| “Vessix Renal Denervation System: So Advanced It's Simple.” [Brochure], Boston Scientific: Advancing science for life, 2013, 6 pages. |
| Asbell, Penny, “Conductive Keratoplasty for The Correction of Hyperopia.” Tr Am Ophth Soc, 2001, vol. 99, 10 pages. |
| Badoer, Emilio, “Cardiac afferents play the dominant role in renal nerve inhibition elicited by vol. expansion in the rabbit.” Am J Physiol Regul Integr Comp Physiol, vol. 274, 1998, 7 pages. |
| Bengel, Frank, “Serial Assessment of Sympathetic Reinnervation After Orthotopic Heart Transplantation: A longitudinal Study Using PET and C-11 Hydroxyephedrine.” Circulation, vol. 99, 1999,7 pages. |
| Benito, F., et al. “Radiofrequency catheter ablation of accessory pathways in infants.” Heart, 78:160-162 (1997). |
| Bettmann, Michael, Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association, Circulation, vol. 97, 1998, 4 pages. |
| Bohm, Michael et al., “Rationale and design of a large registry on renal denervation: the Global Symplicity registry.” EuroIntervention, vol. 9, 2013, 9 pages. |
| Brosky, John, “EuroPCR 2013: CE-approved devices line up for renal denervation approval.” Medical Device Daily, May 28, 2013, 3 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=83002>. |
| Davis, Mark et al., “Effectiveness of Renal Denervation Therapy for Resistant Hypertension.” Journal of the American College of Cardiology, vol. 62, No. 3, 2013, 11 pages. |
| Dibona, G.F. “Sympathetic nervous system and kidney in hypertension.” Nephrol and Hypertension, 11: 197-200 (2002). |
| Dubuc, M., et al., “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter.” J Interv Cardiac Electrophysiol, 2:285-292 (1998). |
| Final Office Action; U.S. Appl. No. 12/827,700; dated Feb. 5, 2013, 61 pages. |
| Geisler, Benjamin et al., “Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension.” Journal of the American College of Cardiology, col. 60, No. 14, 2012, 7 pages. |
| Gelfand, M., et al., “Treatment of renal failure and hypertension.” U.S. Appl. No. 60/442,970, filed Jan. 29, 2003, 23 pages. |
| Gertner, Jon, “Meet The Tech Duo That's Revitalizing the Medical Device Industry.” FAST Company, Apr. 15, 2013, 6:00 AM, 17 pages, <http://www.fastcompany.com/3007845/meet-tech-duo-thats-revitalizing-medical-device-industry>. |
| Golwyn, D. H., Jr., et al. “Percutaneous Transcatheter Renal Ablation with Absolute Ethanol for Uncontrolled Hypertension or Nephrotic Syndrome: Results in 11 Patients with End-Stage Renal Disease.” JVIR, 8: 527-533 (1997). |
| Hall, W. H., et al. “Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor.” Am. J. Roentgenol,174: 1592-1594 (2000). |
| Han, Y.-M, et al., “Renal artery ebolization with diluted hot contrast medium: An experimental study.” J Vasc Interv Radiol, 12: 862-868 (2001). |
| Hansen, J. M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin. Sci, 87: 13-19 (1994). |
| Hendee, W. R. et al. “Use of Animals in Biomedical Research: The Challenge and Response.” American Medical Association White Paper (1988) 39 pages. |
| Hering, Dagmara et al., “Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.” EuroIntervention, vol. 9, 2013, 9 pages. |
| Huang et al., “Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats.” Hypertension 32 (1998) pp. 249-254. |
| Imimdtanz, “Medtronic awarded industry's highest honor for renal denervation system.” The official blog of Medtronic Australasia, Nov. 12, 2012, 2 pages, <http://97waterlooroad.wordpress.com/2012/11/12/medtronic-awarded-industrys-highest-honour-for-renal-denervation-system/>. |
| Kaiser, Chris, AHA Lists Year's Big Advances in CV Research, medpage Today, Dec. 18, 2012, 4 pages, <http://www.medpagetoday.com/Cardiology/PCI/36509>. |
| Kompanowska, E., et al., “Early Effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow.” J Physiol, 531. 2:527-534 (2001). |
| Lee, S.J., et al. “Ultrasonic energy in endoscopic surgery.” Yonsei Med J, 40:545-549 (1999). |
| Linz, Dominik et al., “Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs.” Heart Rhythm, vol. 0, No. 0, 2013, 6 pages. |
| Lustgarten, D.L.,et al., “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias.” Progr Cardiovasc Dis, 41:481-498 (1999). |
| Mabin, Tom et al., “First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.” EuroIntervention, vol. 8, 2012, 5 pages. |
| Mahfoud, Felix et al., “Ambulatory Blood Pressure Changes after Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Circulation, 2013, 25 pages. |
| Mahfoud, Felix et al., “Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.” European Heart Journal, 2013, 9 pages. |
| Mahfoud, Felix et al., “Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension.” Hypertension, 2012, 6 pages. |
| Medical-Dictionary.com, Definition of “Animal Model,” http://medical-dictionary.com (search “Animal Model”), 2005, 1 page. |
| Medtronic, Inc., Annual Report (Form 10-K) (Jun. 28, 2011) 44 pages. |
| Millard, F. C., et al, “Renal Embolization for ablation of function in renal failure and hypertension.” Postgraduate Medical Journal, 65, 729-734, (1989). |
| Oliveira, V., et al., “Renal denervation normalizes pressure and baroreceptor reflex in high renin hypertension in conscious rats.” Hypertension, 19:II-17-II-21 (1992). |
| Ong, K. L., et al. “Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004.” Hypertension, 49: 69-75 (2007) (originally published online Dec. 11, 2006). |
| Ormiston, John et al., “First-in-human use of the OneShot™ renal denervation system from Covidien.” EuroIntervention, vol. 8, 2013, 4 pages. |
| Ormiston, John et al., “Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial.” EuroIntervention, vol. 9, 2013, 5 pages. |
| Pedersen, Amanda, “TCT 2012: Renal denervation device makers play show and tell.” Medical Device Daily, Oct. 26, 2012, 2 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=80880>. |
| Peet, M., “Hypertension and its Surgical Treatment by bilateral supradiaphragmatic splanchnicectomy” Am J Surgery (1948) pp. 48-68. |
| Renal Denervation (RDN), Symplicity RDN System Common Q&A (2011), 4 pages, http://www.medtronic.com/rdn/mediakit/RDN%20FAQ.pdf. |
| Schauerte, P., et al. “Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation.” Circulation, 102:2774-2780 (2000). |
| Schlaich, Markus et al., “Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects.” Curr Hypertens Rep, vol. 14, 2012, 7 pages. |
| Schmid, Axel et al., “Does Renal Artery Supply Indicate Treatment Success of Renal Denervation.” Cardiovasc Intervent Radiol, vol. 36, 2013, 5 pages. |
| Schmieder, Roland E. et al., “Updated ESH position paper on interventional therapy of resistant hypertension.” EuroIntervention, vol. 9, 2013, 9 pages. |
| Sievert, Horst, “Novelty Award EuroPCR 2010.” Euro PCR, 2010, 15 pages. |
| Solis-Herruzo et al., “Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome,” J. Hepatol. 5 (1987), pp. 167-173. |
| Stella, A., et al., “Effects of reversible renal denervation on haemodynamic and excretory functions on the ipsilateral and contralateral kidney in the cat.” Hypertension, 4:181-188 (1986). |
| Stouffer, G. A. et al., “Catheter-based renal denervation in the treatment of resistant hypertension.” Journal of Molecular and Cellular Cardiology, vol. 62, 2013, 6 pages. |
| Swartz, J.F., et al., “Radiofrequency endocardial catheter ablation of accessory atrioventricular pathway atrial insertion sites.” Circulation, 87: 487-499 (1993). |
| Uchida, F., et al., “Effect of radiofrequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites.” PACE, 21:2517-2521 (1998). |
| Verloop, W. L. et al., “Renal denervation: a new treatment option in resistant arterial hypertension.” Neth Heart J., Nov. 30, 2012, 6 pages, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547427/>. |
| Weinstock, M., et al., “Renal denervation prevents sodium retention and hypertension in salt sensitive rabbits with genetic baroreflex impairment.” Clinical Science, 90:287-293 (1996). |
| Wilcox, Josiah N., Scientific Basis Behind Renal Denervation for the Control of Hypertension, ICI 2012, Dec. 5-6, 2012. 38 pages. |
| Worthley, Stephen et al., “Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.” European Heart Journal, vol. 34, 2013, 9 pages. |
| Worthley, Stephen, “The St. Jude Renal Denervation System Technology and Clinical Review.” The University of Adelaide Australia, 2012, 24 pages. |
| Zuern, Christine S., “Impaired Cardiac Baroflex Sensitivity Predicts Response to Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Journal of the American College of Cardiology, 2013, doi: 10.1016/j.jacc.2013.07.046, 24 pages. |
| Miller, Reed, “Finding a Future for Renal Denervation With Better Controlled Trials.” Pharma & Medtech Business Intelligence, Article # 01141006003, Oct. 6, 2014, 4 pages. |
| Papademetriou, Vasilios, “Renal Denervation and Symplicity HTN-3: “Dubium Sapientiae Initium” (Doubt Is the Beginning of Wisdom)”, Circulation Research, 2014; 115: 211-214. |
| Papademetriou, Vasilios et al., “Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions.” Circulation. 2014; 129: 1440-1450. |
| Papademetriou, Vasilios et al., “Catheter-Based Renal Denervation for Resistant Hypertension: 12-Month Results of the EnligHTN | First-in-Human Study Using a Multielectrode Ablation System.” Hypertension. 2014; 64: 565-572. |
| Doumas, Michael et al., “Renal Nerve Ablation for Resistant Hypertension: The Dust Has Not Yet Settled.” The Journal of Clinical Hypertension. 2014; vol. 16, No. 6, 2 pages. |
| Messerli, Franz H. et al. “Renal Denervation for Resistant Hypertension: Dead or Alive?” Healio: Cardiology today's Intervention, May/Jun. 2014, 2 pages. |
| International Search Report and Written Opinion for International App. No. PCT/US2014/026854, dated Oct. 10, 2014, 15 pages. |
| Chinushi et al., “Blood Pressure and Autonomic Responses to Electrical Stimulation of the Renal Arterial Nerves Before and After Ablation of the Renal Artery.” Hypertension, 2013, 61, pp. 450-456. |
| Pokushalov et al., “A Randomized Comparison of Pulmonary Vein Isolation With Versus Without Concomitant Renal Artery Denervation in Patients With Refractory Symptomatic Atrial Fibrillation and Resistant Hypertension.” Journal of the American College of Cardiology, 2012, 8 pages. |
| Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G; “GSR Investigators First report of the Global Symplicity Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.” Hypertension. Apr. 2015;65(4):766-74. |
| Soulis JV1, Fytanidis DK1, Seralidou KV1, Giannoglou GD2, “Wall shear stress oscillation and its gradient in the normal left coronary artery tree bifurcations” Hippokratia 2014, 18, 1: 12-16. |
| Knight et al., “Choosing the optimal wall shear parameter for the prediction of plaque location—a patient-specific computational study in human right coromary arteries.” Elsevier Inc., Aug. 2010, vol. 211, Issue 2, pp. 445-50. |
| Dodge, et al., “Lumen Diameter of Normal Human Coronary Arteries Influence of Age, Sex, Anatomic Variation, and Left Ventricular Hypertrophy or Dilation”, Circulation, 1992, vol. 86 (1), pp. 232-246. |
| Opposition to European Patent No. 2465470, Granted Oct. 28, 2015, Date of Opposition Jul. 27, 2016, 34 pp. |
| U.S. Appl. No. 11/363,867, filed Feb. 27, 2006, 70 pp. |
| U.S. Appl. No. 60/813,589, filed Dec. 29, 2005, 62 pgs. |
| Ureter, https://en.wikipedia.org/wiki/Ureter, Jun. 2016, 6 pgs. |
| Number | Date | Country | |
|---|---|---|---|
| 20150305808 A1 | Oct 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61984533 | Apr 2014 | US | |
| 61984170 | Apr 2014 | US |
